RE: SG018 potential timelines based on hospital admissions - UK29 Jan 2021 20:17
" there’s not a material difference between the two trials’ recruitment"
Is it fair to assume that, considering we are a national priority study (at least on paper)?
Also, I've asked before but I don't think we had that info at the time - are we paying participants? If so, are we paying a lot more than in P2? Especially considering the higher costs of running P3 and involving parexel to speed things up.